tiprankstipranks
Xeris Biopharma sees FY24 revenue $170M-$200M, consensus $188.01M
PremiumThe FlyXeris Biopharma sees FY24 revenue $170M-$200M, consensus $188.01M
2M ago
Xeris Biopharma reports Q4 EPS (10c), consensus (10c)
PremiumThe Fly
Xeris Biopharma reports Q4 EPS (10c), consensus (10c)
2M ago
Options Volatility and Implied Earnings Moves Today, March 06, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 06, 2024
2M ago
Xeris Biopharma price target lowered to $5.50 from $6 at H.C. Wainwright
PremiumThe FlyXeris Biopharma price target lowered to $5.50 from $6 at H.C. Wainwright
5M ago
Xeris Biopharma reports Q3 EPS (9c), consensus (12c)
PremiumThe Fly
Xeris Biopharma reports Q3 EPS (9c), consensus (12c)
6M ago
Xeris Biopharma  tightens FY23 revenue view to $155M-$165M from $145M-$165M
PremiumThe Fly
Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M
6M ago
Xeris Biopharma: 1st patient dosed in study of XP-8121 to treat hypothyroidism
PremiumThe FlyXeris Biopharma: 1st patient dosed in study of XP-8121 to treat hypothyroidism
10M ago
Xeris Pharmaceuticals (XERS) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Xeris Pharmaceuticals (XERS) Q1 Earnings Cheat Sheet
12M ago
Xeris Biopharma announces issuance of U.S. patent covering XeriSol formulations
PremiumThe Fly
Xeris Biopharma announces issuance of U.S. patent covering XeriSol formulations
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100